secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-06-25T21:22:26+00:00
Accession:  0001493152-26-030190
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos extends debt-to-equity conversion deadline with Streeterville to Aug 31, 2026
--------------------------------------------------------------------------------

- Streeterville extends timeframe for converting up to $4.5M debt into perpetual preferred and common stock to August 31, 2026.
- Conversion is contingent on Vivos raising at least $2.6M in equity; occurs dollar-for-dollar up to $4.5M.
- Extension allows Vivos to conduct planned rights offering and maintain Nasdaq listing compliance.
- Original June 5, 2026 agreement had June 15 deadline; Company needed more time to complete equity raise.
- CEO Kirk Huntsman expresses gratitude for Streeterville's cooperation and support on new strategic business model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/0001493152-26-030190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer